Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 3/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.66 |
| ▸ | VKORC1 | Q9BQB6 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8042698 | 0.83 | CYP2C9 (0.86) | NQO1CYP2C9VKORC1KDM4EALDH1A1 | |
| SCHEMBL1649847 | 0.81 | CYP2C9 (0.50) | NQO1CYP2C9KDM4EALDH1A1HSD17B10 | |
| SCHEMBL14078661 | 0.80 | NQO1 (0.73) | NQO1CYP2C9VKORC1 | |
| SCHEMBL32659670 | 0.80 | VKORC1 (0.82) | NQO1CYP2C9VKORC1 | |
| SCHEMBL310481 | 0.80 | VKORC1 (0.82) | NQO1CYP2C9VKORC1 | |
| Phenprocoumon SCHEMBL24500472 | 0.79 | CYP2C9 (1.00) | NQO1CYP2C9VKORC1KDM4EALDH1A1 | |
| Phenprocoumon SCHEMBL43031 | 0.79 | CYP2C9 (1.00) | NQO1CYP2C9VKORC1KDM4EALDH1A1 | |
| Phenprocoumon SCHEMBL29392123 | 0.79 | CYP2C9 (1.00) | NQO1CYP2C9VKORC1KDM4EALDH1A1 | |
| Phenprocoumon SCHEMBL24500477 | 0.79 | CYP2C9 (1.00) | NQO1CYP2C9VKORC1KDM4EALDH1A1 | |
| SCHEMBL18126686 | 0.79 | NQO1 (0.78) | NQO1CYP2C9VKORC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 755 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-103221070-A | Shear controlled release for stenotic lesions and thrombolytic therapies | HARVARD COLLEGE | 2013-07-24 | — | — | CN | claimed |
| EP-2611466-A2 | SHEAR CONTROLLED RELEASE FOR STENOTIC LESIONS AND THROMBOLYTIC THERAPIES | President and Fellows of Harvard College (US) | 2013-07-10 | — | — | EP | claimed |
| US-20130005683-A1 | GLYCINE BETAINE AND ITS USE | MESSADEK JALLAL (BE) | 2013-01-03 | — | — | US | claimed |
| WO-2012074588-A2 | SHEAR CONTROLLED RELEASE FOR STENOTIC LESIONS AND THROMBOLYTIC THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-06-07 | — | — | WO | claimed |
| US-8163806-B2 | Controlled release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-24 | — | — | US | claimed |
| US-20120010284-A1 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-12 | — | — | US | claimed |
| US-8034119-B2 | Delivering an agent to a patient's body | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2011-10-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1387649-B1 | DELIVERING AN AGENT TO A PATIENT'S BODY | BOSTON SCIENT LTD (BB) | 2010-08-04 | — | — | EP | claimed |
| US-20040033223-A1 | Glycine betaine and its use | MESSADEK JALLAL (BE) | 2004-02-19 | — | — | US | claimed |
| EP-1387649-A1 | DELIVERING AN AGENT TO A PATIENT'S BODY | SciMed Life Systems, Inc. (US) | 2004-02-11 | — | — | EP | claimed |
| US-6685745-B2 | Delivering an agent to a patient's body | SCIMED LIFE SYSTEMS, INC. | 2004-02-03 | — | — | US | claimed |
| EP-1309354-A2 | THERAPEUTIC POLYESTERS AND POLYAMIDES | Rutgers, The State University (US) | 2003-05-14 | — | — | EP | claimed |
| US-20020173818-A1 | Delivering an agent to a patient's body | BOSTON SCIENTIFIC SCIMED, INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002091957-A1 | DELIVERING AN AGENT TO A PATIENT'S BODY | SCIMED LIFE SYSTEM, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| WO-2002062322-A2 | GLYCINE BETAINE AND ITS USE AS ANTI-HEMORRHAGIC AGENT | MESSADEK JALLAL (BE) | 2002-08-15 | — | — | WO | claimed |
| US-20020071822-A1 | Therapeutic polyesters and polyamides | POLYMERIX CORPORATION | 2002-06-13 | — | — | US | claimed |
| WO-2002009768-A2 | THERAPEUTIC POLYESTERS AND POLYAMIDES | RUTGERS, THE STATE UNIVERSITY (US) | 2002-02-07 | — | — | WO | claimed |
| US-4334020-A | Method of producing L-glutamic acid by fermentation | AJINOMOTO COMPANY INCORPORATED (JP) | 1982-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010284-A1 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, AADAC, LGMN | NQO1 1517/4885CYP2C9 2823/4885VKORC1 4406/4885 |
| US-20020071822-A1 | Therapeutic polyesters and polyamides | NPEPPS, PAICS, PUF60 | NQO1 3920/4885CYP2C9 3155/4885VKORC1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.